Tamara Crockett, Esq
President and Chief Executive Officer
Tamara Crockett brings a wealth of experience in technology commercialization, intellectual property, technology transfer, start-ups and early stage commercialization to this project. She has over 25 years of experience in technology development, intellectual property, contract negotiation and commercialization of emerging technologies. She most recently served as Senior Counsel for Accenture, plc, a leading multinational technology consulting firm. She is licensed to practice law in the states of NY, MA, DC and AZ.
Meredith hay, ph.d.
Founder and Chief Science Officer
Dr. Hay is the visionary and one of the inventors of the founding technology. She has over 25 years of experience in neuroscience and cardiovascular neurophysiology. She is the former Executive Vice President and Chief Operating Officer for the University of Arizona for former Vice President for Research, University of Iowa. She currently is a tenured professor at the University of Arizona College of Medicine. Dr. Hay has generated over $10 M in external R&D funding and nearly 20 NIH and related grants.
bruce coull, m.d.
Chief Medical Officer
Dr. Coull is internationally known for his expertise in stroke, vascular neurology and brain inflammation. He has 35+ years' experience in neourology, including management of clinical trials. He is Professor of Neurology and Medicine and Vice Dean for Clinical Affairs at the University of Arizona College of Medicine.
Director of Regulatory Affairs and Manufacturing
Peter has 30+ years' experience in leading CMC and regulatory activities in the biomedical industry. Peter has held various positions, including Chief Regulatory Officer, Chief Operations Officer, Vice President of CMC and Head of Operations for several US-based companies. Peter started his career at Genentech, where he held several technical and leadership positions in pharmaceutical development and manufacturing and drug delivery.
Rodney Lax, Ph.D.
Consultant Peptide Product Development
Rodney has more than 35 years' experience in peptide chemistry, manufacturing and therapeutics development.. In 2003, Rodney became Senior Director of Business Development at Polypeptide, Inc. located in California.
Kathleen rodgers, ph.d.
Director of Toxicology
Dr. Rodgers is an expert in pharmacology and toxicology with extensive experience in angiotensin peptides and small molecule Mas agonists. Kathy is the author of several hundred research articles and inventor on numerous patent s relating to Ang-(1-7). She is certified by the American Board of Toxicology. Currently, she serves as Associate Director Translational Neuroscience and Professor of Pharmacology at the University of Arizona.
Nina Ossanna, ph.d.
Director of Product Development
Dr. Ossanna brings broad experience in both the technical and business side of the pharmaceutical industry. Dr. Ossanna manages product development and partner relationships and has extensive experience in IND development and multicenter clinical trails.